alexa Ballooning mitral valve syndrome | Finland| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences
  • 30th European Heart Diseases and Heart Failure Congress
    February 18-19, 2019 Amsterdam, Netherlands
  • Middle East Heart Congress
    March 18-20, 2019 Dubai, UAE
  • 5th World Heart Congress
    March 27- 28, 2019 Sydney, Australia
  • 2nd Global Cardiology Summit
    May 13-14, 2019 Perth, Australia
  • 31st Annual Cardiologists Conference
    June 17-19, 2019 Rome, Italy
  • European Cardiology Congress
    July 01-02, 2019 Prague, Czech Republic
  • 6th Global Experts Meeting on Cardiovascular Pharmacology
    July 12-13, 2019 Yokohama, Japan
  • 27th International Conference & Exhibition on Cardiology and Cardiovascular Medicine
    July 26-27, 2019 Kyoto, Japan
  • 27th International Congress on Cardiology and medical interventions
    July 31-August 01, 2019 Chicago, USA
  • 5th World Congress on Cardiology and Cardiovascular Therapeutics
    August 12-13, 2019 Tokyo, Japan
  • 7th World Heart Congress
    August 19- 20, 2019 Vienna, Austria
  • European Heart Congress
    October 23-24, 2019 Amsterdam, Netherlands
  • 32nd European Cardiology Conference
    October 24-26, 2019 Zurich, Switzerland

Ballooning Mitral Valve Syndrome

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Ballooning mitral valve syndrome

    Stenosis means narrowing of an opening, such as a heart valve. Stenosis of the mitral valve limits the forward flow of blood from the left atrium to the left ventricle. This may cause a back-up of blood and fluid in the lungs. Mitral stenosis most commonly develops many years after a person has had rheumatic fever, although many patients diagnosed with mitral stenosis don't recall ever having the illness.

  • Ballooning mitral valve syndrome

    Causes: Diagnosed with mitral stenosis don’t recall ever having the illness. During rheumatic fever, the valve becomes Mitral stenosis most commonly develops many years after a person has had rheumatic fever, although many patients inflamed. Over time, the leaflets of the inflamed valve stick together and become scarred, rigid and thickened, limiting its ability to open completely.

    \Symptoms: Many of the symptoms of mitral stenosis, such as shortness of breath and fatigue, result from a back-up of blood in the lungs. Other symptoms of mitral stenosis may include quick weight gain; weakness; dizziness; swelling in the ankles, feet and/or abdomen (edema); and/or heart palpitations (irregular heartbeat).

  • Ballooning mitral valve syndrome

    Treatment :A balloon valvotomy is the preferred treatment for mitral valve stenosis. It is a procedure that widens the mitral valve so that blood flows more easily through the heart. A balloon valvotomy is a minimally invasive procedure. A doctor uses a thin flexible tube (catheter) that is inserted through an artery in the groin or arm and threaded into the heart. When the tube reaches the narrowed mitral valve, a balloon device located on the tip of the catheter is quickly inflated. The narrowed or fused mitral valve leaflets are separated and stretched open as the balloon presses against them. This process increases the size of the mitral valve opening and allows more blood to flow from the left atrium into the left ventricle.

  • Ballooning mitral valve syndrome

    Statistics: The mean follow-up time was 7.3 +/- 1.4 years. After adjustment for baseline characteristics by the propensity score method, there was a statistically significant survival benefit for the patients who underwent MVP (p = 0.02). Risk factors for death were preoperative unstable angina pectoris (relative risk ratio, 4.4; 95% confidence interval, 2.2 to 8.8), age older than 60 years (relative risk ratio, 1.1; 95% confidence interval, 1.0 to 1.1), use of mitral prosthesis (relative risk ratio, 2.7; 95% confidence interval, 1.4 to 5.3), preoperative renal insufficiency (relative risk ratio, 1.0; 95% confidence interval, 1.0 to 1.007), and preoperative cerebrovascular disorder (relative risk ratio, 2.7; 95% confidence interval, 1.0 to 5.3). The quality of life of the MVP and MVR groups did not differ from each other, but the MVP and the MVR patients had lower energy and mobility scores than an age- and sex-matched reference population. The 30-day postoperative mortality rate was 10.0% (n = 18); rates were 7.1% after MVRep and 20.5% after MVR (p = 0.013). The additive EuroSCORE (p <0.0001, area under the ROC curve: 0.804, 95% CI 0.689-0.919, SE 0.059), as well as logistic EuroSCORE (p <0.0001, area under the ROC curve: 0.806, 95% CI 0.695-0.918, SE 0.057) were predictors of 30-day postoperative death. The 10-year overall survival rate from any cause of death was 74.7%. Additive and logistic EuroSCOREs were significantly higher in the MVR group compared to the MVRep group (p <0.0001 in both cases), and also among operative survivors. Patients who underwent MVR had a significantly poorer long-term survival than those with MVRep (p = 0.01). Both the additive EuroSCORE (p <0.0001) and logistic EuroSCORE (p = 0.003) were predictors of late, all-cause mortality. Both scores remained significant predictors of late outcome also when adjusted for type of surgery (MVRep versus MVR). Survival was particularly dismal in patients with an additive EuroSCORE >6 (at 10 years, 54.4% versus 86.6%, p <0.00001) or a logistic EuroSCORE >4% (at 10 years, 58.7% versus 86.6%, p <0.00001).

Expert PPTs

Speaker PPTs


High Impact List of Articles

Conference Proceedings